Compare SBLK & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBLK | INSP |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.2B |
| IPO Year | 2007 | 2018 |
| Metric | SBLK | INSP |
|---|---|---|
| Price | $22.77 | $56.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 16 |
| Target Price | $22.00 | ★ $101.07 |
| AVG Volume (30 Days) | ★ 1.9M | 1.1M |
| Earning Date | 02-25-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | N/A | ★ 179.43 |
| EPS | N/A | ★ 4.89 |
| Revenue | N/A | ★ $82,050,000.00 |
| Revenue This Year | $14.05 | $8.44 |
| Revenue Next Year | N/A | $8.60 |
| P/E Ratio | $47.06 | ★ $11.52 |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $12.06 | $53.11 |
| 52 Week High | $27.20 | $172.95 |
| Indicator | SBLK | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 34.26 |
| Support Level | $18.09 | $53.11 |
| Resistance Level | $27.20 | $84.26 |
| Average True Range (ATR) | 0.88 | 2.89 |
| MACD | -0.41 | 0.23 |
| Stochastic Oscillator | 22.64 | 14.61 |
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.